|
See related Uromitexan inj information |
|
|
|
Manufacturer |
Baxter Healthcare |
|
Distributor |
Zuellig |
|
Contents |
Mesna |
|
Indications |
Prevention of urotoxic effects of oxazaphosphorines. |
|
Dosage |
Adult IV inj Per dose: 20% of dose of oxazaphosphorine, administered at time zero (time of administration of oxazaphosphorine) repeated after 4 & 8 hr. W/ a continuous oxazaphosphorine infusion: 20% of the oxazaphosphorine dose given as a bolus inj at time zero, followed by a continuous infusion of Uromitexan of up to 100% of the initial oxazaphosphorine dose. Continue infusion for a further 6-12 hr after the end of the oxazaphosphorine administration. |
|
Special Precautions |
Protective effect applies only to the urinary tract. |
|
Adverse Drug Reactions |
GI effects, headache, malaise, skin rash. Allergic symptoms (rare).
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Uromitexan injection |
|
Uromitexan 400 mg/4 mL x 15's |
|
|
|
Manufacturer: |
Baxter Healthcare |
|
Distributor: |
Zuellig |
|
|
|
|
